NASDAQ:CNST Constellation Pharmaceuticals (CNST) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free CNST Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$33.99▼$33.9950-Day Range$33.63▼$33.9952-Week Range$17.00▼$39.30VolumeN/AAverage Volume940,325 shsMarket Capitalization$1.63 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Constellation Pharmaceuticals alerts: Email Address Ad DTIthe most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click Here About Constellation Pharmaceuticals Stock (NASDAQ:CNST)Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Read More Ad Behind the MarketsThe Small Biotech with a BIG Cancer SolutionThere's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.Get the full story here >>> CNST Stock News HeadlinesApril 20, 2023 | chron.comYour guide to Constellation Field, home of the Sugar Land Space CowboysMarch 8, 2023 | forbes.comConstellation SoftwareMarch 28, 2024 | DTI (Ad)CBOE shift unlocks new weekend income strategyYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend. January 15, 2023 | thestreet.comConstellation Brands Inc. NewsDecember 11, 2022 | cnet.comStarlink Explained: What You Need to Know About Elon Musk's Satellite Internet ServiceJanuary 19, 2022 | bizjournals.comFormer execs at bluebird, Constellation join VC firm Third RockSee More Headlines Receive CNST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Constellation Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2021Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CNST CUSIP21036U206 CIK29806 Webwww.constellationpharma.com Phone617-714-0555FaxN/AEmployees154Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-126,360,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-33.12% Return on Assets-29.92% Debt Debt-to-Equity RatioN/A Current Ratio15.39 Quick Ratio15.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.63 per share Price / Book3.94Miscellaneous Outstanding Shares47,915,000Free FloatN/AMarket Cap$1.63 billion OptionableNot Optionable Beta2.59 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Jigar RaythathaPres, CEO & DirectorMs. Emma Reeve (Age 60)Chief Financial Officer Comp: $562.98kDr. Patrick Trojer Ph.D. (Age 48)Sr. VP & Chief Scientific Officer Comp: $556.52kMs. Karen Higgins Valentine J.D. (Age 49)Sr. VP, Chief Legal Officer & Gen. Counsel Comp: $535.93kDr. Jeffrey Humphrey M.D. (Age 59)Chief Medical Officer Comp: $462.25kDr. Danny ReinbergCo-FounderDr. Yang Shi Ph.D.Co-FounderDr. David AllisCo-FounderMr. Mohan Bala Ph.D.Chief Operating OfficerMr. Ronald Aldridge (Age 67)Sr. Director of Investor Relations More ExecutivesKey CompetitorsProtagonist TherapeuticsNASDAQ:PTGXAgios PharmaceuticalsNASDAQ:AGIOMorphicNASDAQ:MORFDynavax TechnologiesNASDAQ:DVAXEdgewise TherapeuticsNASDAQ:EWTXView All Competitors CNST Stock Analysis - Frequently Asked Questions How were Constellation Pharmaceuticals' earnings last quarter? Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) announced its earnings results on Sunday, May, 9th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.79) by $0.05. What is Jigar Raythatha's approval rating as Constellation Pharmaceuticals' CEO? 10 employees have rated Constellation Pharmaceuticals Chief Executive Officer Jigar Raythatha on Glassdoor.com. Jigar Raythatha has an approval rating of 100% among the company's employees. This puts Jigar Raythatha in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Constellation Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Applied Materials (AMAT), Inovio Pharmaceuticals (INO), Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and AT&T (T). When did Constellation Pharmaceuticals IPO? Constellation Pharmaceuticals (CNST) raised $80 million in an IPO on Thursday, July 19th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager. This page (NASDAQ:CNST) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Constellation Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.